Table 1 Clinical characteristics of the study population (N = 61)

Male, n(%)

58(95.08%)

Age (years)

56.93 ± 11.85

BMI (kg/m²)

24.46 ± 3.04

BSA (m²)

1.78 ± 0.16

Systolic blood pressure (mmHg)

123.9 ± 21.24

Diastolic blood pressure (mmHg)

77.95 ± 13.42

Heart rate (bpm)

78.79 ± 12.12

creatine kinase (U/L)

1337.07 ± 1431.32

Peak CK-MB (U/L)

132.13 ± 155.32

hs-TNI (ug/L)

24.88 ± 23.71

NT-proBNP (ng/L)

1049.27 ± 1298.49

ALT (U/L)

41.86 ± 28.51

AST (U/L)

146.29 ± 147.18

HDL-C (mmol/L)

0.92 ± 0.21

LDL-C (mmol/L)

2.44 ± 0.75

TG (mmol/L)

1.64 ± 1.91

PT (s)

14.04 ± 1.24

APTT (s)

67.86 ± 54.69

Killip classification (I, II, III, IV)

I, n(%)

19(31.14%)

II, n(%)

23(37.70%)

III, n(%)

15(24.59%)

IV, n(%)

4(6%)

Hypertension, n(%)

20(32.78%)

Diabetes, n(%)

17(27.86%)

Dyslipidemia, n(%)

12(19.67%)

Culprit vessel

LAD, n(%)

25(40.98%)

LCX, n(%)

6(9.83%))

RCA, n(%)

30(49.18%)

Single-vessel disease, n(%)

32(52.45%)

Electrocardiographic evidence of

Anterior myocardial infarction, n (%)

26(42.6%)

Lateral myocardial infarction, n (%)

3(4.91%)

Inferior myocardial infarction, n (%)

32(52.45%)

Door-to-balloon time(h)

6.81 ± 2.89

Aspirin, n (%)

61(100%)

Clopidogrel / Ticagrelor, n (%)

40(65.57%)

Statin, n (%)

61(100%)

Beta-blocker, n (%)

15(24.59%)

ACEI/ARB, n (%)

12(19.6%)

Aldosterone antagoist, n (%)

23(37.70%)

SGLT2 inhibitor, n (%)

16(26.22%)